FDA Approves Nilotinib for Paediatric Patients with Newly Diagnosed or Resistant/Intolerant Ph-Positive CML in Chronic Phase

Approval is based on results in paediatric patients from CAMN107A2120 and CAMN107A2203 studies

On 22 March 2018, the US Food and Drug Administration (FDA) approved nilotinib (TASIGNA, Novartis Pharmaceuticals Corporation) for paediatric patients 1 year of age or older with newly diagnosed Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.

Approval was based on results in 69 paediatric patients with Ph+ CML-CP from two open-label, single-arm, multi-centre trials: CAMN107A2120 (NCT01077544) in paediatric patients with Ph+ CML-CP resistant or intolerant to imatinib or dasatinib (n = 11) and CAMN107A2203 (NCT01844765) in paediatric patients with Ph+ CML-CP resistant or intolerant to imatinib or dasatinib (n = 33) and newly diagnosed Ph+ CML-CP (n = 25). In both trials, patients received nilotinib 230 mg/m2 twice daily, rounded to the nearest 50 mg dose (maximum single dose of 400 mg) in 28-day treatment cycles. The median time on treatment was 13.8 months (range: 0.7 to 30.9 months).

In patients with resistant or intolerant Ph+ CML-CP, the major molecular response rate (MMR; BCR-ABL/ABL ≤0.1% IS) was 40.9% (18/44, 95% CI: 26.3%, 56.8%) at 12 cycles. In patients with newly diagnosed Ph+ CML-CP, the MMR rate was 60.0% (15/25, 95% CI: 38.7%, 78.9%) at 12 cycles. In patients with resistant or intolerant CML, the cumulative MMR rate was 47.7% (21/44) by cycle 12. In patients with newly diagnosed CML, the cumulative MMR rate was 64.0% (16/25) by cycle 12.

Among patients with resistant or intolerant CML, 4.5% of patients achieved BCR-ABL/ABL ≤0.0032% IS (MR4.5) by the cut-off date. Among patients with newly diagnosed CML, the percentage who achieved MR4.5 was 28.0%.

The safety profile in paediatric patients is similar to the known safety profile in adults with Ph+ CML-CP. Common adverse reactions (greater than 20%) were hyperbilirubinemia, thrombocytopenia, rash, neutropenia, lymphopenia, alanine aminotransferase (ALT) increased, headache, anaemia, pyrexia, nausea, upper respiratory tract infection, aspartate aminotransferase increased, and vomiting. The most common grade 3/4 adverse reactions were ALT increased and hyperbilirubinemia. Increase in QTcF greater than 30 msec from baseline was observed in 17 patients (25%). No patient had an absolute QTcF of greater than 500 msec or QTcF increase of greater than 60 msec from baseline.

The recommended paediatric dose is 230 mg/m2 orally twice daily, rounded to the nearest 50 mg dose (maximum single dose of 400 mg).

Full prescribing information is available here.  

FDA granted this application priority review and orphan drug designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.